Glycotest
About us
Management Team and Board
Scientific and Medical Advisors
Glycotest Investor Presentation
Investors
Technology
Clinical Data
Intellectual Property
News
Contact us
Glycotest
About us
Management Team and Board
Scientific and Medical Advisors
Glycotest Investor Presentation
Investors
Technology
Clinical Data
Intellectual Property
News
Contact us
Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent.
January 13, 2021
-
News
-
No comments
-
Posted by
glycotest
NEXT POST →
More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.
Leave a Comment
Your feedback is valuable for us. Your email will not be published.
Cancel Reply
Save my name, email, and website in this browser for the next time I comment.
Please wait...
Submit Comment
Related News
Other posts that you should not miss.
More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.
November 3, 2020
-
News
Read More →
Posted by
glycotest
1 MIN READ
Glycotest, Inc. Receives $3 Million Second Tranche of $10 Million Series A Financing
November 21, 2019
-
News
New York, NY—November 21, 2019. Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company…
Read More →
Posted by
Webmaster
3 MIN READ
Glycotest is developing a new Test for Detecting Early Stage Liver Cancer with the revolutionary approach of using Glycoproteins as Biomarkers – CEOCFO Magazine
September 3, 2019
-
News
Glycotest19-CEOCFOMagazine-Interview.pdf
Read More →
Posted by
Webmaster
1 MIN READ
Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent. | Glycotest Diagnostics